What is Champions Oncology Price-to-Operating-Cash-Flow?
As of today (2024-04-30), Champions Oncology's share price is $4.85.
Champions Oncology's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jan. 2024 was $-0.37. Hence, Champions Oncology's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Champions Oncology's Price-to-Operating-Cash-Flow or its related term are showing as below:
During the past 13 years, Champions Oncology's highest Price-to-Operating-Cash-Flow Ratio was 509.23. The lowest was 7.02. And the median was 49.17.
Champions Oncology's Cash Flow from Operations per share for the
three
months ended in Jan. 2024 was $-0.07.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jan. 2024 was $-0.37.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Champions Oncology was -192.30% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 6.10% per year.
During the past 13 years, Champions Oncology's highest 3-Year average Operating Cash Flow per Share Growth Rate was 57.90% per year. The lowest was -218.90% per year. And the median was 2.60% per year.
Champions Oncology Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Champions Oncology's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Champions Oncology Price-to-Operating-Cash-Flow Chart
|
Champions Oncology Annual Data
|
|
Trend |
Apr14 |
Apr15 |
Apr16 |
Apr17 |
Apr18 |
Apr19 |
Apr20 |
Apr21 |
Apr22 |
Apr23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
68.79 |
31.51 |
- |
16.73 |
16.79 |
|
Champions Oncology Quarterly Data
|
|
Apr19 |
Jul19 |
Oct19 |
Jan20 |
Apr20 |
Jul20 |
Oct20 |
Jan21 |
Apr21 |
Jul21 |
Oct21 |
Jan22 |
Apr22 |
Jul22 |
Oct22 |
Jan23 |
Apr23 |
Jul23 |
Oct23 |
Jan24 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
10.25 |
16.79 |
500.00 |
- |
- |
Competitive Comparison of Champions Oncology's Price-to-Operating-Cash-Flow
For the Biotechnology subindustry, Champions Oncology's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Champions Oncology's Price-to-Operating-Cash-Flow falls into.
Champions Oncology Price-to-Operating-Cash-Flow Calculation
Champions Oncology's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 4.85 | / | -0.37 |
| = | |
Champions Oncology's Share Price of today is $4.85.
Champions Oncology's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.37.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Champions Oncology (Champions Oncology) Business Description
Traded in Other Exchanges
Address
One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.
Executives
| Daniel Newman Mendelson |
director |
COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR, SUITE 900, BETHESDA MD 20817 |
| Ronnie Morris |
director, officer: President |
855 N. WOLFE STREET, SUITE 619, BALTIMORE MD 21205 |
| Philip P. Breitfeld |
director |
ONE UNIVERSITY PLAZA, SUITE 307, HACKENSACK NJ 07601 |
| New Enterprise Associates 14, L.p. |
10 percent owner |
1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
| Neeraj Agrawal |
10 percent owner |
ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210 |
| Roger H Lee |
10 percent owner |
ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210 |
| Michael Maurice Brown |
10 percent owner |
ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210 |
| Battery Management Corp. |
10 percent owner |
ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210 |
| R David Tabors |
10 percent owner |
ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210 |
| Jesse Feldman |
10 percent owner |
ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210 |
| Joel Ackerman |
director, officer: Chief Executive Officer |
COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR SUITE 900, BETHESDA MD 20817 |
| Patrick J Kerins |
10 percent owner |
|
| Ryan D Drant |
10 percent owner |
1119 ST PAUL STREET, BALTIMORE MD 21202 |
| Nea 14 Gp, Ltd |
10 percent owner |
1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
| Nea Partners 14, L.p. |
10 percent owner |
1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Champions Oncology (Champions Oncology) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CSBR has been successfully added to your